Pilot Randomised Controlled Trial of the Feasibility and Acceptability of Family‐Based Time Limited Eating to Treat Obesity
Pediatric Obesity · 2026-03 · 21 (3)
DOI: 10.1111/ijpo.70103 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Pediatric Obesity, online erschienen am 19.03.2026. Verfasst von Amy C Gross und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Pediatric Obesity Medicine, University of Minnesota, Minneapolis, USA. Hauptthemen laut MEDLINE: Pediatric Obesity, Feeding Behavior. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, National Institutes of Health's National Center for Advancing Translational Sciences.
Abstract (Originalsprache)
Background
Time‐limited eating (TLE) shows promise as an adult obesity treatment; little is known in paediatrics or families.
Objective
To assess the feasibility and acceptability of family‐based TLE.
Methods
This was a 12 week pilot randomized trial comparing family‐based TLE to dietary standard of care (SOC). Families included a child aged 3–9 years and caretaker, both with obesity. TLE received instruction to end eating after the evening meal and otherwise eat ad libitum. SOC received dietary instruction. Primary outcomes, feasibility and acceptability, were measured through retention, intervention burden (i.e., treatment time) and satisfaction surveys. Anthropometrics were measured at baseline and 12 weeks. Between‐arm comparisons of BMI percentile above the median (%BMIp50) used mixed effects models to account for family clustering; comparisons of adult BMI and child BMI percentage of the 95th percentile (%BMIp95) used two‐sample t ‐tests.
Results
Eighteen families enrolled (10 TLE; 8 SOC). Retention was 94% (100% TLE, 88% SOC). TLE required significantly less total treatment time than SOC [84.3 vs. 140.9 min; p < 0.001]. Satisfaction was high; 89% TLE and 100% SOC would recommend their treatment. Overall, SOC reduced mean %BMIp50 more than TLE (mean difference: −3.9; p = 0.001), with no difference in change in child %BMIp95 between arms (−0.2, p = 0.92), but with SOC reducing parental BMI more than TLE (−1.6, p = 0.002).
Conclusions
Family‐based TLE was feasible and acceptable and required less time to implement than SOC, suggesting TLE could be an accessible dietary intervention for families. Fully powered studies are needed to determine BMI efficacy. Trial Registration: ClinicalTrials.gov : NCT05107726
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Pediatric Obesity Medicine, University of Minnesota, Minneapolis, USA.
- Department of Pediatrics, University of Minnesota, Minneapolis, USA.
- School of Public Health Division of Biostatistics and Health Data Science, University of Minnesota, Minneapolis, USA.
- Clinical and Translational Science Institute, University of Minnesota, Minneapolis, USA.
- Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, University of Minnesota, Minneapolis, USA.
ORCID-Profile: Amy C Gross, Lisa S Chow
Förderung
- NCATS NIH HHS
- National Institutes of Health's National Center for Advancing Translational Sciences
Zitieren
APA
Gross, A. C., Helgeson, E. S., Wang, Q., & Chow, L. S. (2026). Pilot Randomised Controlled Trial of the Feasibility and Acceptability of Family‐Based Time Limited Eating to Treat Obesity. Pediatric Obesity, 21(3). https://doi.org/10.1111/ijpo.70103
Vancouver
Gross AC, Helgeson ES, Wang Q, Chow LS. Pilot Randomised Controlled Trial of the Feasibility and Acceptability of Family‐Based Time Limited Eating to Treat Obesity. Pediatric Obesity. 2026;21(3). doi:10.1111/ijpo.70103
BibTeX
@article{Gross2026,
author = {Gross, Amy C and Helgeson, Erika S and Wang, Qi and Chow, Lisa S},
title = {Pilot Randomised Controlled Trial of the Feasibility and Acceptability of Family‐Based Time Limited Eating to Treat Obesity},
journal = {Pediatric Obesity},
year = {2026},
volume = {21},
number = {3},
doi = {10.1111/ijpo.70103}
}
EUVIMED